Synagis
NDC Package 66658-231-01
Package Information
Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14) ]. Marketed by Swedish Orphan Biovitrum Ab (publ), this product is identified by NDC 66658-231 and is authorized under FDA application BLA103770.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66658 - Swedish Orphan Biovitrum Ab (publ)
- 66658-231 - Synagis
- 66658-231-01 - 1 mL in 1 VIAL, SINGLE-DOSE
- 66658-231 - Synagis
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66658-231-01 identifies a specific commercial package of 1 ml in 1 vial, single-dose of Synagis, labeled by Swedish Orphan Biovitrum Ab (publ). This product is billed per "ML" milliliter and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Swedish Orphan Biovitrum Ab (publ) on June 19, 1998. The current certification is valid through July 31, 2026.
How is this Swedish Orphan Biovitrum Ab (publ) product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66658023101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.